Dr. Glenn Fitzpatrick is a clinical trials leader with a background that runs from molecular biology through life sciences consulting to clinical operations. His PhD at RCSI explored whether exosomes from infected endothelial cells could identify therapeutic pathways for sepsis. It's a disease killing 11 million people annually with no major breakthroughs in decades.
Before his PhD, he engineered CHO cell lines containing microRNA 'sponges' to enhance cellular productivity at the National Institute for Cellular Biotechnology. After it, he built fluorescent microscopy systems to observe how clinical strains from infective endocarditis patients anchor to endothelial cells under physiological flow, analysing the strongest binders to identify novel therapeutic targets.
The pivot to life sciences consulting at Accenture taught him how to scale scientific expertise. Most consultants spoke business. Glenn could sit with Roche and Pfizer's bench scientists, understand their workflows at a molecular level, then translate that into digital solutions that actually worked. He got good at closing the gap between what scientists need and what tech teams build.
Now he's at Vial Australia Pty Ltd in Sydney. He recently executed one of the world's first NAM-enabled FIH trials using a half-life extended monoclonal antibody for IBD, and he's continuing to expand clinical operations across Australia.